<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426334</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-03454</org_study_id>
    <secondary_id>NCI-2011-03454</secondary_id>
    <secondary_id>CDR0000709681</secondary_id>
    <secondary_id>10-1401</secondary_id>
    <secondary_id>10-1401</secondary_id>
    <secondary_id>8890</secondary_id>
    <secondary_id>P30CA046934</secondary_id>
    <nct_id>NCT01426334</nct_id>
    <nct_alias>NCT01456988</nct_alias>
  </id_info>
  <brief_title>Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate</brief_title>
  <official_title>Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best way to give dasatinib and&#xD;
      cyclosporine in treating patients with chronic myelogenous leukemia (CML) refractory or&#xD;
      intolerant to imatinib mesylate. Dasatinib may stop the growth of cancer cells by blocking&#xD;
      some of the enzymes needed for cell growth. Cyclosporine may help dasatinib work better by&#xD;
      making cancer cells more sensitive to the drug. Giving dasatinib together with cyclosporine&#xD;
      may be an effective treatment for CML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define the safety and tolerability of cyclosporine A in combination with dasatinib in&#xD;
      adults with Bcr-Abl+ chronic myelogenous leukemia in chronic phase, or when used in specified&#xD;
      patients with accelerated phase CML.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess pharmacokinetic parameters of dasatinib when combined with cyclosporine.&#xD;
&#xD;
      II. To assess whether the combination of dasatinib and cyclosporine alters T cell number and&#xD;
      function.&#xD;
&#xD;
      III. To assess the feasibility of determining phosphorylation of Src in peripheral blood&#xD;
      mononuclear cells by flow cytometry as a surrogate measure of dasatinib activity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive dasatinib orally (PO) once daily (QD) on days 1-28 and cyclosporine PO twice&#xD;
      daily (BID) on days 8-28. Treatment repeats every 28 days for 4 months in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo peripheral blood sample collection at baseline and periodically during&#xD;
      treatment for pharmacokinetic and pharmacodynamic studies and T-cell number and function by&#xD;
      flow cytometry.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of combining dasatinib and cyclosporine, as assessed by the incidence of adverse events and serious adverse events in this patient population</measure>
    <time_frame>Up to 4 weeks post-treatment</time_frame>
    <description>Serious adverse events, toxicity, and patient withdrawals/discontinuations will be determined by the severity, duration, causality, seriousness, and type of event as defined in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles of patients taking dasatinib alone versus dasatinib with cyclosporine</measure>
    <time_frame>At baseline and on days 7, 21, 49, 77, and 105</time_frame>
    <description>Exposure to dasatinib will be determined and compared using peak levels (Cmax) and areas under the curve (AUC). Paired t-tests will be used to determine statistical significance.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (dasatinib and cyclosporine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (dasatinib and cyclosporine)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib and cyclosporine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib and cyclosporine)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (dasatinib and cyclosporine)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed chronic myelogenous&#xD;
             leukemia (CML), Philadelphia chromosome positive (Ph+)&#xD;
&#xD;
          -  Patients must have a diagnosis of:&#xD;
&#xD;
               -  de novo chronic phase Ph+ CML, and not have received therapy with a tyrosine&#xD;
                  kinase inhibitor (TKI) for more than 2 weeks prior to enrollment&#xD;
&#xD;
               -  OR chronic phase Ph+ CML refractory to or with intolerance of treatment with&#xD;
                  imatinib or nilotinib therapy; patients being treated with dasatinib who have&#xD;
                  refractory disease may be considered for inclusion, at the discretion of the PIs,&#xD;
                  if other therapeutic options are not deemed likely to be efficacious (e.g.&#xD;
                  previous intolerance or refractoriness to nilotinib); evaluation for and&#xD;
                  consideration of hematopoietic stem cell transplantation as appropriate to the&#xD;
                  patient's condition by the patient's primary treating hematologist/oncologist&#xD;
                  should occur prior to enrollment in this trial&#xD;
&#xD;
               -  OR chronic phase Ph+ CML, without complete molecular remission after 3 months of&#xD;
                  treatment with imatinib, nilotinib or dasatinib&#xD;
&#xD;
               -  OR accelerated phase Ph+ CML, for which allogeneic hematopoietic stem cell&#xD;
                  transplantation is being planned, and for which no cytotoxic chemotherapy is&#xD;
                  planned prior to conditioning, and can be reasonably expected to participate for&#xD;
                  a minimum of one month prior to transplantation&#xD;
&#xD;
               -  OR accelerated phase Ph+ CML, for which allogeneic hematopoietic stem cell&#xD;
                  transplantation is not a therapeutic option (due to age or lack of acceptable&#xD;
                  donor, for example), and can be reasonably expected to participate for a minimum&#xD;
                  of one month&#xD;
&#xD;
          -  Chronic phase CML shall be defined by the presence of fewer than 15% blasts, fewer&#xD;
             than 20% basophils, and fewer than 30% blasts plus promyelocytes in the peripheral&#xD;
             blood and bone marrow, no extramedullary involvement except liver and spleen, and no&#xD;
             evidence of clonal evolution (O'Brien et al., 2003)&#xD;
&#xD;
          -  Treatment failure/refractory disease shall be defined as less than complete&#xD;
             hematologic response at 3 months, no cytogenetic response at 6 months, less than&#xD;
             partial cytogenetic response at 12 months, less than complete cytogenetic response at&#xD;
             18 months, OR loss of CHR, loss of CCyR, clonal chromosomal abnormalities, detection&#xD;
             of imatinib insensitive mutations, or 1 log increase in BCR-ABL transcript level from&#xD;
             best molecular response documented on 2 samples at least one month apart (Baccarani et&#xD;
             al., 2009)&#xD;
&#xD;
          -  Intolerance of TKI therapy shall be defined by non-hematologic toxic effects of any&#xD;
             grade leading to intermittent or chronic non-compliance with, repeated dose reduction&#xD;
             or delays in continuous dosing, or discontinuation of Imatinib&#xD;
&#xD;
          -  Accelerated phase CML shall be defined as the presence of &gt;= 15-29% blasts, &gt;= 20%&#xD;
             basophils, or &gt;= 30% blasts plus promyelocytes in the peripheral blood or bone marrow,&#xD;
             thrombocytopenia unrelated to therapy, or evidence of cytogenetic clonal evolution&#xD;
             (Kantarjian et al., 1993)&#xD;
&#xD;
          -  Prior Therapy&#xD;
&#xD;
               -  Patients must have discontinued imatinib, nilotinib or dasatinib at least 7 days&#xD;
                  prior to starting study therapy; this washout period may be omitted at the&#xD;
                  discretion of the PIs, if it is determined that the washout may adversely affect&#xD;
                  patient care&#xD;
&#xD;
               -  Patients must discontinue hydroxyurea or interferon at least 7 days prior to&#xD;
                  starting study therapy&#xD;
&#xD;
          -  Life expectancy of greater than 1 month&#xD;
&#xD;
          -  ECOG performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mcL&#xD;
&#xD;
          -  Absolute CD4+ count &gt;= 350/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) =&lt; 2.5 X institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60&#xD;
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  The effects of dasatinib on the developing human fetus are unknown; for this reason&#xD;
             and because PTK inhibitors are known to be teratogenic, women of childbearing&#xD;
             potential must have a negative pregnancy test within 7 days of study entry; women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation and for a minimum of 30 days following discontinuation of study&#xD;
             therapy; should a woman become pregnant or suspect she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform her treating physician&#xD;
             immediately; lactating women must agree not to nurse a child while on this trial or&#xD;
             within 30 days of discontinuation of study therapy&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
             prior to entering the study or failure to recover from adverse events (except&#xD;
             alopecia) to Grade =&lt; 1 or to baseline (if there is persistent, chronic, stable Grade&#xD;
             2), due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Known brain metastases exclude patients from this clinical trial because such patients&#xD;
             have a poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events;&#xD;
             in addition, patients who have active brain metastases may benefit from other&#xD;
             concurrent therapy such as radiation or radiosurgery, and should be considered for the&#xD;
             most appropriate clinical therapy that may provide symptom relief&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to dasatinib or cyclosporine&#xD;
&#xD;
          -  Patients who require concurrent treatment with any medications or substances that are&#xD;
             potent inhibitors or inducers of CYP3A4 are ineligible; efforts should be made to&#xD;
             switch patients with a seizure disorder who are taking enzyme-inducing anticonvulsant&#xD;
             agents to other medications&#xD;
&#xD;
          -  Patients who require concurrent treatment with proarrhythmic potential&#xD;
&#xD;
          -  QTc prolongation (defined as a QTc interval &gt;= 480 msec) or other significant ECG&#xD;
             abnormalities&#xD;
&#xD;
          -  Use of antithrombotic and/or anti-platelet agents (e.g., warfarin, heparin, low&#xD;
             molecular weight heparin, aspirin, and/or ibuprofen); exception: patients with CML who&#xD;
             have significantly elevated platelet counts taking anagrelide are eligible; patients&#xD;
             who require &lt; 2 mg of warfarin per day for central venous catheter prophylaxis are&#xD;
             allowed on this study&#xD;
&#xD;
          -  Patients with any condition (e.g., gastrointestinal tract disease resulting in an&#xD;
             inability to take oral medication or a requirement for IV alimentation, prior surgical&#xD;
             procedures affecting absorption, or active peptic ulcer disease) that impairs their&#xD;
             ability to swallow and retain dasatinib tablets are excluded; tablets may not be&#xD;
             crushed prior to administration&#xD;
&#xD;
          -  Patients may not have any clinically significant cardiovascular disease, defined as&#xD;
             NYHA class III or higher and as follows:&#xD;
&#xD;
               -  Myocardial infarction or ventricular tachyarrhythmia within 6 months&#xD;
&#xD;
               -  Prolonged QTc &gt;= 480 msec (Fridericia correction)&#xD;
&#xD;
               -  Ejection fraction less than institutional normal&#xD;
&#xD;
               -  Major conduction abnormality (unless a cardiac pacemaker is present)&#xD;
&#xD;
          -  Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath,&#xD;
             chest pain, etc.) should be evaluated by a baseline echocardiogram with or without&#xD;
             stress test as needed in addition to electrocardiogram (EKG) to rule out QTc&#xD;
             prolongation; the patient may be referred to a cardiologist at the discretion of the&#xD;
             principal investigator; patients with underlying cardiopulmonary dysfunction should be&#xD;
             excluded from the study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, the following:&#xD;
             ongoing or active infection; history of significant bleeding disorder, including&#xD;
             congenital (von Willebrand's disease) or acquired (anti-factor VIII antibodies)&#xD;
             disorders; large pleural effusions; or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because animal studies with dasatinib have&#xD;
             shown embryolethality and fetal skeletal alterations at non-toxic maternal doses;&#xD;
             because there is an unknown but potential risk for adverse events in nursing human&#xD;
             infants secondary to treatment of the mother with dasatinib, breastfeeding should be&#xD;
             discontinued if the mother is treated with dasatinib&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with dasatinib; in addition, these&#xD;
             patients are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy; appropriate studies will be undertaken in patients&#xD;
             receiving combination antiretroviral therapy when indicated&#xD;
&#xD;
          -  Known congenital or acquired immunodeficiency&#xD;
&#xD;
          -  CD4+ count less than 350/Âµl&#xD;
&#xD;
          -  Mutation in Bcr-Abl known to confer resistance to dasatinib; (N.B. patients for whom&#xD;
             Bcr-Abl mutations have not been assessed, will have this assessment in screening; they&#xD;
             will be allowed to enroll and initiate therapy; if screening analysis reveals Bcr-Abl&#xD;
             mutation known to confer resistance to dasatinib, the patient will be discontinued&#xD;
             from study participation)&#xD;
&#xD;
          -  Prior hematopoietic stem cell transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Porter</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Cancer Center - Anschutz Cancer Pavilion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

